Patients who were receiving no other treatment for pulmonary arterial hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) prostanoids were eligible.

Concomitant treatment with oral phosphodiesterase type 5 inhibitors, oral or inhaled prostanoids, calcium-channel blockers, or l-arginine was allowed, provided that the patient had been receiving ...

In this Perspectives article, we describe the role of prostanoids in bladder physiology, summarize the findings from animal model and human studies and discuss the clinical use of prostanoids in ...

The drug given at 10 mg/day led to a 45% reduction (p<0.001) in a clinical primary end point that included death, initiation of IV or subcutaneous prostanoids, or worsening of PAH. The benefit was ...

These results indicate that, although prostanoids may play a systemic role in changes in blood flow distribution during hypoxia, they do not appear to act locally on resistance vessels in the brain.